Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
2 Months : From Oct 2019 to Dec 2019
By Colin Kellaher
Bristol-Myers Squibb Co. (BMY) Tuesday said a phase 3 study evaluating its cancer drug Opdivo plus low-dose Yervoy combined with chemotherapy met its primary endpoint of superior overall survival for the first-line treatment of advanced non-small cell lung cancer.
The New York biopharmaceutical company said the study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy versus chemotherapy alone.
Non-small cell lung cancer, or NSCLC, is the most common type of lung cancer, accounting for up to 85% of diagnoses.
Bristol-Myers said it plans to complete a full evaluation of the study results, which it said build on the benefit the combination of Opdivo plus Yervoy has previously shown in other cancers.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
October 22, 2019 08:44 ET (12:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.